1.
Kayaal
p S.O. Tıbbi Farmakoloji. Hacettepe-Taş Kitapçılık Ltd. Şti. 2000; Dokuzuncu Baskı. 1042-1043.
2. Shimada SG, Otterness IG, Stitt JT. A study ofthe mechanism of action ofthe
mild analgesic dipyrone. Agents Actions 1994;41(3-4):188-92.
3. Giri AK, Mukhopadhyay A. Mutagenicity assay in salmonella and in vivo sister
chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives. MutationResearch. 1998;420: 15-25.
4. Woodbury DM, Fingl E. Analgesic, antipyretic, antiinflammatory agents and drugs
employed in the therapy ofgout, in: L.S. Goodman A. Gilman (EDS). The
Pharmacological Basis ofTherapeutics, Macmillan Publishing,NewYork.1975; 334-39.
5. Greenstone M, Harhey B, Gabriel R, Bevan G. Acute nephrotic syndrome with
reversible renal failure after phenylbutazone. Br. Med. J. 1981; 282: 950-951.
6. Chaplin S. Bone marrow depression due to mainser in, phenylbutazone,
oxyphenylbutazone and chloramphenicol. Ad. Drug React. Acute poisoning Rev. 1986; 5: 97-136.
7. WarsefNW. Teratogenicity ofphenylbutazone in mice. Bull. Zool. Soc. Egypt. 1979;
29: 16-21.
8. Schardein JL, Blatz AT, Woosley ET, Kaump DH.
S.D.Ü. Tıp pak.
Derg
. 2006:13(1)/ 27-31
Gökçimen, Metamizol Sodyumun Etkileri
31
Reproduction studies on sodium meclofenamate in comparison to aspirin and phenylbutazone. Toxicol. Appl. Pharmacol. 1969; 15: 46-55.
9. Kari F, Bucher J, Haseman J, Euitis S, HuffJ. Long-term exposure to the antiinflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in
mice. Natl. Inst. Environ. Health Sci. 1995; 86: 252¬263.
10. Klein W, Kocsis F, Scherer G, Altmann HZ. Experimantal effects of
oxyphenylbutazone and prednisolone on the DNA matabolism in Syrian hamsters. Rheumatology. 1980; 39: 301-308.
11. Donaubauer H, Kief H, Kramer M, Krief K, Mayer D, Schuitz E. Investigations on the carcinogenicity ofdipyrone in rats. Toxicol App Pharm.
1985;
81(3): 443-451.
12. Kramer M. Chronic toxicity ofpyrazolones: the problem ofnitrosation. BritishJournal ofClinicalPharmacology. 1980; 10(2): 313-317.
13. Maj S, Lis Y. The incidince ofmetamizole sodium-induced agranulocytosis Poland.
J. Int. Med. Res. 2002; 30(5): 488-95.
14. White WJ. The use oflaboratory animals in toxicologic research. In: Principles and
method oftoxicology. (AW. Hayes. Ed). 4th ed. Taylor&Francis, Philadelphia. 2001; 774-818.
15. Gökçimen A, Aydın G, Karaöz E, Malas MA, Öncü M. Effect ofdiclofenac sodium administration during pregnancy in the postnatal period. Fetal Diagn Ther. 2001; 16: 417-422.
16. Bar-Oz B, Clementi M, Di Giantonio E, Greenberg R, Beer M, Merlob P, Arnon J,
Ornoy A, Zimmerman DM, Berkovitch M. Metamizol (dipyrone, optalgin) in pregnancy, is it safe ? A prospective comparative study. Eur J Obstet Gynecol ReprodBiol. 2005; 1:119 (2):176-9.
17. Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol. 2005; 60 (11):
821-9.
18. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated
with dipyrone (metamizole). Eur J Clin Pharmacol. 2002; 58 (4): 265-274.
19. Farker K, Nassr N, Huck F, Zerle G, Rosenkranz B, Schmieder G, HoffmannA.
Dipyrone and diclofenac do not influence creatinine-clearance, inulin-clearance or
PAH-clearance in healthy male volunteers. Int J Clin Pharmacol Ther. 1995; 33
(3):125-30.
20. Kumagai H, Kawaura A, Shibata M, Otsuka H. Carcinogenicity of dipyrone in
(C57BL/6 X C3H)F1 mice. JNatl Cancer Inst. 1983; 71 (6): 1295-7.
21. Heinemeyer G, Gramm HJ, Roots I, Dennhardt R, Simgen W. The kinetics of
metamizol and its metabolites in critical-care patients
with acute renal dysfunction.
Eur J Clin Pharmacol. 1993; 45 (5): 445-50.
22. Jaszczuk E, Graczyk M, Oszukowski P, Brzezinski P. Anaphylactic shock leading
to death in a young woman after oral administration
ofmetamizole (Pyralginum-
Polfa)--case report. Przegl Lek. 1999; 56 (2): 175-6.
Thank you for copying data from http://www.arastirmax.com
